Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Deep venous thrombosis.

José A López1, Clive Kearon, Agnes Y Y Lee

  • 1Baylor College of Medicine, Thrombosis Research Section, Houston, TX 77030, USA.

Hematology. American Society of Hematology. Education Program
|November 25, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-Valent Rhodium and Iridium Assemblies Directed by Uracilate and Guaninate Linkers.

Inorganic chemistry·2026
Same author

The diagnostic performance of the YEARS and Pulmonary Embolism Graduated D-dimer algorithms in patients with prior venous thrombosis suspected of pulmonary embolism.

Research and practice in thrombosis and haemostasis·2026
Same author

Factors associated with aggregate formation in cold-stored platelets.

Vox sanguinis·2026
Same author

Breaking the Mold: Electrophilic Hydrophosphanation Emerges.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026
Same author

Targeting von Willebrand factor selectively under inflammatory conditions.

bioRxiv : the preprint server for biology·2026
Same author

Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism.

The New England journal of medicine·2026

Venous thromboembolism (VTE) involves deep venous thrombosis (DVT) or pulmonary embolism (PE). This chapter explores VTE initiation mechanisms, recurrence risk stratification, and cancer-associated VTE management with low-molecular weight heparins (LMWHs).

Area of Science:

  • Hematology
  • Vascular Biology
  • Oncology

Background:

  • Venous thromboembolism (VTE), encompassing deep venous thrombosis (DVT) and pulmonary embolism (PE), is a prevalent medical condition with significant morbidity and mortality.
  • Despite its frequency, the precise mechanisms initiating VTE, individualized treatment strategies based on recurrence risk, and management in specific contexts like cancer remain areas requiring further elucidation.

Purpose of the Study:

  • To elucidate the pathogenic mechanisms underlying VTE initiation, particularly in the absence of overt vessel injury.
  • To outline strategies for risk stratification to tailor anticoagulant therapy duration and type, minimizing recurrence and bleeding risks.
  • To review the current understanding and management of VTE associated with malignancy, including the role of low-molecular weight heparins (LMWHs).

Related Experiment Videos

Main Methods:

  • Section I proposes a model for VTE initiation involving tissue factor (TF)-bearing microvesicles from monocyte/macrophage lineage interacting with activated endothelial cells.
  • Section II discusses risk factors for VTE recurrence and presents an algorithm for risk-stratified anticoagulant therapy.
  • Section III reviews evidence on VTE in cancer patients, focusing on the efficacy and survival benefits of LMWHs.

Main Results:

  • A model suggests TF-bearing microvesicles and endothelial activation, potentially influenced by hypoxia and inflammation, initiate coagulation.
  • Patient risk factors (major, minor reversible, or persistent) significantly influence VTE recurrence rates after anticoagulation cessation.
  • LMWHs demonstrate improved survival in advanced cancer patients with VTE, potentially through anti-neoplastic effects beyond anticoagulation.

Conclusions:

  • Understanding microvesicle-mediated coagulation and endothelial activation offers insights into VTE pathogenesis, especially in inflammatory states.
  • Individualized risk assessment is crucial for optimizing anticoagulant therapy duration and minimizing adverse events.
  • LMWHs are the preferred anticoagulants for VTE in cancer patients due to efficacy, safety, and potential survival benefits.